Lyra Therapeutics (NSDQ:LYRA) announced today that it initiated the Phase 3 Enlighten I trial for its LYR-210 treatment. Watertown, Massachusetts-based Lyra's Phase 3 Enlighten I clinical trial will evaluate LYR-210, delivered through Lyra's … [Read More...] about Lyra Therapuetics initiates Phase 3 trial for chronic rhinosinusitis treatment
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Lyra Therapuetics initiates Phase 3 trial for chronic rhinosinusitis treatment
Lyra Therapeutics (NSDQ:LYRA) announced today that it initiated the Phase 3 Enlighten I trial for its LYR-210 treatment. Watertown, Massachusetts-based Lyra's Phase 3 Enlighten I clinical trial will evaluate LYR-210, delivered through Lyra's … [Read More...] about Lyra Therapuetics initiates Phase 3 trial for chronic rhinosinusitis treatment
MIT team working on all-in-one diabetes management devices
MIT researchers are touting a platform aimed at helping patients maintain healthy glucose levels by streamlining the diabetes management process. The MIT researchers say it's hard for people with diabetes to maintain a treatment regimen. Typically … [Read More...] about MIT team working on all-in-one diabetes management devices
Fractyl Health touts preliminary data from diabetes reversal study
Fractyl Health this week announced encouraging interim feasibility data from its diabetes reversal technology study. Lexington, Massachusetts–based Fractyl's Revita-T2Di long-term open-label cohort assessed eight patients followed through at least … [Read More...] about Fractyl Health touts preliminary data from diabetes reversal study
FDA grants IDE approval for Capillary Biomedical’s 7-day-wear infusion set
Capillary Biomedical announced today that it received FDA investigational device exemption (IDE) for its SteadiFlow infusion technology. Irvine, California-based Capillary Biomedical designed its new SteadiFlow seven-day-wear infusion set … [Read More...] about FDA grants IDE approval for Capillary Biomedical’s 7-day-wear infusion set
Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a … [Read More...] about Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
FDA grants new drug approval to Glenmark’s rhinitis-treating nasal spray
Glenmark Pharmaceuticals announced today that it received FDA approval for a new drug application (NDA) for Ryaltrais. Ryaltris, a fixed-dosed, prescription drug product nasal spray treats symptoms of seasonal allergic rhinitis in adults and … [Read More...] about FDA grants new drug approval to Glenmark’s rhinitis-treating nasal spray
Fort HealthCare, Ivenix partner on infusion safety effort with smart pump
Ivenix announced today that it successfully implemented its smart infusion pump at the Fort HealthCare hospital in Wisconsin. Boston-based Ivenix designed its Ivenix Infusion System, a combination of a large-volume infusion pump and infusion … [Read More...] about Fort HealthCare, Ivenix partner on infusion safety effort with smart pump
Roche launches its connected blood glucose meter in Europe
Roche announced today that it launched its Cobas Pulse system in select countries accepting CE mark approval in Europe. Basel, Switzerland–based Roche designed its Cobas Pulse system to combine the form factor of a high-performance blood glucose … [Read More...] about Roche launches its connected blood glucose meter in Europe
Dali Medical Devices completes first implementation of SAN-Light passive safety needle
Dali Medical Devices announced today that it completed the first commercial implementation of the SAN-Light passive safety needle. Tel Aviv, Israel-based Dali designed the SAN-Light single-use, sterile, hypodermic safety needle for compatibility … [Read More...] about Dali Medical Devices completes first implementation of SAN-Light passive safety needle
Glytec partners with Roche to enhance insulin dosing decision support software
Glytec announced today that it entered into a strategic partnership with Roche Diagnostics USA for a digital health collaboration. Waltham, Massachusetts-based Glytec's partnership combines its FDA-cleared Glucommander insulin dosing decision … [Read More...] about Glytec partners with Roche to enhance insulin dosing decision support software
In case you missed it
- Dexcom CEO touts unprecedented performance of G7 in clinical trial, awaits FDA decision
- Medtronic CEO confirms FDA warning could affect approval timing for next-gen diabetes tech
- Hugo, renal denervation and diabetes businesses to drive growth despite setbacks, Medtronic CEO says
- FDA clears Glaukos’ iPrime
- Abbott CEO touts future of biowearables in first-ever healthcare company keynote at CES
- Laborie acquires exclusive license for drug-coated baloon treatment for urethral strictures
- Senseonics expects FDA approval for next-gen 180-day CGM in ‘coming weeks’
- Glytec garners cybersecurity certification for insulin management system
- Xeris Biopharma enters agreement for $30M private placement
- Your favorite articles from Drug Delivery Business News in 2021
- Novo Nordisk completes acquisition of Dicerna Pharmaceuticals
- FDA approves injectable atopic dermatitis treatment from LEO Pharma
- Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires
- Zacks says Medtronic will gain from expanded CMS coverage for CGMs
- CMS expands Medicare coverage to CGMs that integrate with Medtronic insulin pumps
Clinical Trials
Lyra Therapuetics initiates Phase 3 trial for chronic rhinosinusitis treatment
Lyra Therapeutics (NSDQ:LYRA) announced today that it initiated the Phase 3 Enlighten I trial for its LYR-210 treatment. Watertown, Massachusetts-based Lyra’s Phase 3 Enlighten I clinical trial will evaluate LYR-210, delivered through Lyra’s proprietary XTreo drug-eluting implant, in adult, surgically naïve chronic rhinosinusitis (CRS) patients. The company designed LYR-210 for delivery in a brief, non-invasive, […]
Fractyl Health touts preliminary data from diabetes reversal study
Fractyl Health this week announced encouraging interim feasibility data from its diabetes reversal technology study. Lexington, Massachusetts–based Fractyl’s Revita-T2Di long-term open-label cohort assessed eight patients followed through at least four weeks having been treated. The company’s Revita system resurfaces the upper intestine lining (duodenal mucosa) to treat metabolic disease in patients with insulin-treated type 2 […]
FDA grants IDE approval for Capillary Biomedical’s 7-day-wear infusion set
Capillary Biomedical announced today that it received FDA investigational device exemption (IDE) for its SteadiFlow infusion technology. Irvine, California-based Capillary Biomedical designed its new SteadiFlow seven-day-wear infusion set technology to significantly extend patient wear time to a week and maintain insulin stability. The SteadiSet infusion set, powered by the SteadiFlow technology platform, features an integrated […]
PharmaJet partner announces COVID-19 vaccine trial with needle-free injection tech
PharmaJet announced today that one of its pharmaceutical partners, Nykode Therapeutics, has begun a trial for a COVID-19 vaccine with PharmaJet’s needle-free injection technology. Nykode’s Phase 1/2 clinical trial will specifically address the emerging SARS-CoV-2 variants, with the DNA-based vaccines delivered intramuscularly with PharmaJet’s Stratis needle-free injection system. The vaccines are designed to be tailored […]
Virpax reports positive non-human study results for topical spray film that treats chronic pain
Virpax Pharmaceuticals (NSDQ:VRPX) today reported positive results from a study of its Epoladerm treatment for chronic pain management. Berwyn, Pennsylvania-based Virpax designed Epoladerm, one of its lead investigational products, for managing pain associated with osteoarthritis of the knee. According to a news release, the company reported positive results following the completion of a toxicology and […]
